Shopping Cart 0
Cart Subtotal
USD 0

MannKind Corp (MNKD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

MannKind Corp (MannKind) is a biopharmaceutical company that develops and commercializes inhaled therapeutic products for patients suffering from diabetes and pulmonary arterial hypertension. Its flagship product, Afrezza is a US FDA approved rapid-action inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The product consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. The company develops products based on its proprietary Technosphere formulation technology. It has manufacturing facility in Danbury, Connecticut and sells its product through wholesale distributors and specialty pharmacies. MannKind is headquartered in California, the US.

MannKind Corp (MNKD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

MannKind Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

MannKind Corp, Medical Devices Deals, 2012 to YTD 2018 10

MannKind Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

MannKind Corp, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

MannKind Enters into Distribution Agreement with Tanner Pharma 12

MannKind to Enter into Marketing and Distribution Agreement with Cipla 13

MannKind and Biomm Enter into Distribution Agreement 14

MannKind Partners with JDRF 15

Licensing Agreements 16

United Therapeutics Enters into Licensing Agreement with MannKind 16

Receptor Life Sciences Enters into Licensing Agreement with MannKind 17

Colby Enters Into Licensing Agreement With MannKind For Cancer Immunotherapy Products 18

MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton's Tyrosine Kinase Inhibitors 20

Equity Offering 21

MannKind Raises USD28 Million in Private Placement of Shares 21

Mannkind to Raise USD61 Million in Private Placement of Shares 23

MannKind Plans to Raise Funds through Private Placement of Shares upon Exercise of Warrants 25

MannKind Raises USD36.2 Million in Private Placement of Shares 26

Mannkind Raises USD50 Million in Private Placment of Shares 27

MannKind Announces Public Offering Of Common Stock For USD 50 Million 29

MannKind Completes Public Offering Of Common Stock And Warrants For USD 92 Million 30

MannKind Completes Public Offering Of Units For USD 86 Million 32

Debt Offering 34

MannKind Completes First Tranche Of Private Placement Of Notes For USD 40 Million 34

MannKind Corp-Key Competitors 36

MannKind Corp-Key Employees 37

MannKind Corp-Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Recent Developments 39

Strategy And Business Planning 39

Sep 05, 2018: MannKind and United Therapeutics to advance dry powder treprostinil 39

Financial Announcements 40

Nov 01, 2018: MannKind reports 2018 third quarter financial results 40

Aug 02, 2018: MannKind Reports 2018 Second Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET 42

May 09, 2018: MannKind Reports 2018 First Quarter Financial Results 44

Feb 27, 2018: MannKind Reports 2017 Fourth Quarter and Full Year Financial Results 45

Nov 07, 2017: MannKind Reports 2017 Third Quarter Financial Results 47

Aug 07, 2017: MannKind Reports 2017 Second Quarter Financial Results 49

May 10, 2017: MannKind Reports 2017 First Quarter Financial Results 51

Mar 16, 2017: MannKind Reports 2016 Fourth Quarter and Full Year Financial Results 52

Corporate Communications 53

Jun 25, 2018: MannKind Set to Join Russell 3000 Index 53

Feb 06, 2018: MannKind Names David Kendall As Chief Medical Officer 54

Jul 17, 2017: Steven Binder Joins MannKind as Chief Financial Officer 55

Jul 12, 2017: Patrick McCauley Joins MannKind as Chief Commercial Officer 56

Jan 04, 2017: MannKind Announces Key Addition to Its Executive Management Ranks 57

Product News 58

08/17/2018: NUI Galway finds new treatment strategy for breast cancer relapse 58

Mar 08, 2017: MannKind and Charles Mattocks Announce "REVERSED"-America's First Docu-Series Tackling Diabetes 59

02/01/2017: MannKind Announces Launch of New Titration Pack and Field Force Expansion to Accelerate Afrezza Growth 60

Other Significant Developments 61

Jan 09, 2017: MannKind Receives USD 30.6 Million From Sanofi 61

Appendix 62

Methodology 62

About GlobalData 62

Contact Us 62

Disclaimer 62


List Of Figure

List of Figures

MannKind Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

MannKind Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

MannKind Corp, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

MannKind Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

MannKind Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

MannKind Corp, Deals By Therapy Area, 2012 to YTD 2018 9

MannKind Corp, Medical Devices Deals, 2012 to YTD 2018 10

MannKind Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

MannKind Enters into Distribution Agreement with Tanner Pharma 12

MannKind to Enter into Marketing and Distribution Agreement with Cipla 13

MannKind and Biomm Enter into Distribution Agreement 14

MannKind Partners with JDRF 15

United Therapeutics Enters into Licensing Agreement with MannKind 16

Receptor Life Sciences Enters into Licensing Agreement with MannKind 17

Colby Enters Into Licensing Agreement With MannKind For Cancer Immunotherapy Products 18

MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton's Tyrosine Kinase Inhibitors 20

MannKind Raises USD28 Million in Private Placement of Shares 21

Mannkind to Raise USD61 Million in Private Placement of Shares 23

MannKind Plans to Raise Funds through Private Placement of Shares upon Exercise of Warrants 25

MannKind Raises USD36.2 Million in Private Placement of Shares 26

Mannkind Raises USD50 Million in Private Placment of Shares 27

MannKind Announces Public Offering Of Common Stock For USD 50 Million 29

MannKind Completes Public Offering Of Common Stock And Warrants For USD 92 Million 30

MannKind Completes Public Offering Of Units For USD 86 Million 32

MannKind Completes First Tranche Of Private Placement Of Notes For USD 40 Million 34

MannKind Corp, Key Competitors 36

MannKind Corp, Key Employees 37

MannKind Corp, Other Locations 38

MannKind Corp, Subsidiaries 38

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

MannKind Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

MannKind Corp (MannKind) is a biopharmaceutical company that develops and commercializes inhaled therapeutic products for patients suffering from diabetes and pulmonary arterial hypertension. Its flagship product, Afrezza is a US FDA approved rapid-action inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The product consists of a dry powder formulation of human insulin delivered from a small and portable inhaler. The company develops products based on its proprietary Technosphere formulation technology. It has manufacturing facility in Danbury, Connecticut and sells its product through wholesale distributors and specialty pharmacies. MannKind is headquartered in California, the US.

MannKind Corp (MNKD)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

MannKind Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

MannKind Corp, Medical Devices Deals, 2012 to YTD 2018 10

MannKind Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

MannKind Corp, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

MannKind Enters into Distribution Agreement with Tanner Pharma 12

MannKind to Enter into Marketing and Distribution Agreement with Cipla 13

MannKind and Biomm Enter into Distribution Agreement 14

MannKind Partners with JDRF 15

Licensing Agreements 16

United Therapeutics Enters into Licensing Agreement with MannKind 16

Receptor Life Sciences Enters into Licensing Agreement with MannKind 17

Colby Enters Into Licensing Agreement With MannKind For Cancer Immunotherapy Products 18

MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton's Tyrosine Kinase Inhibitors 20

Equity Offering 21

MannKind Raises USD28 Million in Private Placement of Shares 21

Mannkind to Raise USD61 Million in Private Placement of Shares 23

MannKind Plans to Raise Funds through Private Placement of Shares upon Exercise of Warrants 25

MannKind Raises USD36.2 Million in Private Placement of Shares 26

Mannkind Raises USD50 Million in Private Placment of Shares 27

MannKind Announces Public Offering Of Common Stock For USD 50 Million 29

MannKind Completes Public Offering Of Common Stock And Warrants For USD 92 Million 30

MannKind Completes Public Offering Of Units For USD 86 Million 32

Debt Offering 34

MannKind Completes First Tranche Of Private Placement Of Notes For USD 40 Million 34

MannKind Corp-Key Competitors 36

MannKind Corp-Key Employees 37

MannKind Corp-Locations And Subsidiaries 38

Head Office 38

Other Locations & Subsidiaries 38

Recent Developments 39

Strategy And Business Planning 39

Sep 05, 2018: MannKind and United Therapeutics to advance dry powder treprostinil 39

Financial Announcements 40

Nov 01, 2018: MannKind reports 2018 third quarter financial results 40

Aug 02, 2018: MannKind Reports 2018 Second Quarter Financial Results Conference Call to Begin Today at 5:00 PM ET 42

May 09, 2018: MannKind Reports 2018 First Quarter Financial Results 44

Feb 27, 2018: MannKind Reports 2017 Fourth Quarter and Full Year Financial Results 45

Nov 07, 2017: MannKind Reports 2017 Third Quarter Financial Results 47

Aug 07, 2017: MannKind Reports 2017 Second Quarter Financial Results 49

May 10, 2017: MannKind Reports 2017 First Quarter Financial Results 51

Mar 16, 2017: MannKind Reports 2016 Fourth Quarter and Full Year Financial Results 52

Corporate Communications 53

Jun 25, 2018: MannKind Set to Join Russell 3000 Index 53

Feb 06, 2018: MannKind Names David Kendall As Chief Medical Officer 54

Jul 17, 2017: Steven Binder Joins MannKind as Chief Financial Officer 55

Jul 12, 2017: Patrick McCauley Joins MannKind as Chief Commercial Officer 56

Jan 04, 2017: MannKind Announces Key Addition to Its Executive Management Ranks 57

Product News 58

08/17/2018: NUI Galway finds new treatment strategy for breast cancer relapse 58

Mar 08, 2017: MannKind and Charles Mattocks Announce "REVERSED"-America's First Docu-Series Tackling Diabetes 59

02/01/2017: MannKind Announces Launch of New Titration Pack and Field Force Expansion to Accelerate Afrezza Growth 60

Other Significant Developments 61

Jan 09, 2017: MannKind Receives USD 30.6 Million From Sanofi 61

Appendix 62

Methodology 62

About GlobalData 62

Contact Us 62

Disclaimer 62


List Of Figure

List of Figures

MannKind Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

MannKind Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

MannKind Corp, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

MannKind Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

MannKind Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

MannKind Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

MannKind Corp, Deals By Therapy Area, 2012 to YTD 2018 9

MannKind Corp, Medical Devices Deals, 2012 to YTD 2018 10

MannKind Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

MannKind Enters into Distribution Agreement with Tanner Pharma 12

MannKind to Enter into Marketing and Distribution Agreement with Cipla 13

MannKind and Biomm Enter into Distribution Agreement 14

MannKind Partners with JDRF 15

United Therapeutics Enters into Licensing Agreement with MannKind 16

Receptor Life Sciences Enters into Licensing Agreement with MannKind 17

Colby Enters Into Licensing Agreement With MannKind For Cancer Immunotherapy Products 18

MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton's Tyrosine Kinase Inhibitors 20

MannKind Raises USD28 Million in Private Placement of Shares 21

Mannkind to Raise USD61 Million in Private Placement of Shares 23

MannKind Plans to Raise Funds through Private Placement of Shares upon Exercise of Warrants 25

MannKind Raises USD36.2 Million in Private Placement of Shares 26

Mannkind Raises USD50 Million in Private Placment of Shares 27

MannKind Announces Public Offering Of Common Stock For USD 50 Million 29

MannKind Completes Public Offering Of Common Stock And Warrants For USD 92 Million 30

MannKind Completes Public Offering Of Units For USD 86 Million 32

MannKind Completes First Tranche Of Private Placement Of Notes For USD 40 Million 34

MannKind Corp, Key Competitors 36

MannKind Corp, Key Employees 37

MannKind Corp, Other Locations 38

MannKind Corp, Subsidiaries 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

MannKind Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.